Death from Mast Cell Leukemia: a Young Patient with Longstanding Cutaneous Mastocytosis Evolving Into Fatal Mast Cell Leukemia

Total Page:16

File Type:pdf, Size:1020Kb

Death from Mast Cell Leukemia: a Young Patient with Longstanding Cutaneous Mastocytosis Evolving Into Fatal Mast Cell Leukemia CASE REPORTS Pediatric Dermatology Vol. 29 No. 5 605–609, 2012 Death from Mast Cell Leukemia: A Young Patient with Longstanding Cutaneous Mastocytosis Evolving into Fatal Mast Cell Leukemia Rattanavalai Chantorn, M.D.,*, and Tor Shwayder, M.D. *Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, Department of Pediatric Dermatology, Henry Ford Hospital, Detroit, Michigan Abstract: Mastocytosis is a broad term used for a group of disorders characterized by accumulation of mast cells in the skin with or without extracutaneous involvement. The clinical spectrum of the disease varies from only cutaneous lesions to highly aggressive systemic involvement such as mast cell leukemia. Mastocytosis can present from birth to adult- hood. In children, mastocytosis is usually benign, and there is a good chance of spontaneous regression at puberty, unlike adult-onset disease, which is generally systemic and more severe. Moreover, individuals with systemic mastocytosis may be at risk of developing hematologic malignancies. We describe a girl who presented to us with a solitary mastocytoma at age 5 and later developed maculopapular cutaneous mastocytosis. At age 23, after an episode of anaphylactic shock, a bone marrow examination revealed mast cell leukemia. She ultimately died despite aggressive chemotherapy and bone marrow transplantation. Mastocytosis is characterized by the abnormal common forms of CM in childhood. The excoriation growth and infiltration of mast cells (MC) in various of lesions causes hives and perilesional erythema, tissues and is classified into two broad categories: which characterizes Darier’s sign (Fig. 3). SM is cutaneous mastocytosis (CM) and systemic mastocy- characterized by multifocal MC infiltrates with or tosis (SM) (1). The course of mastocytosis is variable without skin involvement and is markedly more and is dependent on the subtype and age of onset common in adults than in children. Mast cell (2–4). Mast cell disease in children is usually only leukemia is a rare variant of SM, with few cutaneous and not associatedwithsystemicor cases reported in the literature and usually associated malignant disorders. In adults, MC disease can with grave prognosis (6–12). The purpose of this be systemic and progressive (4). Mastocytosis affects article is to report a case of longstanding childhood infants and children twice as frequently as adults (5). CM evolving to fatal MC leukemia during young Mastocytoma and urticaria pigmentosa (UP) are adulthood. Address correspondence to Tor Shwayder, M.D., Director, Pediatric Dermatology, Henry Ford Hospital, Detroit, MI 48202, or e-mail: [email protected]. DOI: 10.1111/j.1525-1470.2011.01650.x Ó 2012 Wiley Periodicals, Inc. 605 606 Pediatric Dermatology Vol. 29 No. 5 September ⁄ October 2012 CASE REPORT that were positive for Darier’s sign (Fig. 3). Otherwise, review of systems was normal. She denied any symptom A girl had been diagnosed with solitary mastocytoma of histamine release, including flushing, palpitation, since 5 years of age (Fig. 1). Her first presentation was a diarrhea, shortness of breath, headaches, and bone pain. red-brown thumb print–sized plaque in front of the left Because her underlying cutaneous disease was gradually ear that had history of bullous formation after blunt spreading, she was carefully examined. General physical trauma (Fig. 2). Skin biopsy confirmed the diagnosis of examination, blood pressure, pulse, and respiration were cutaneous MC disease at age 5 (outside punch biopsy) all normal. Complete blood count, liver function test, and age 19, when this lesion was removed completely. renal function test, and urinalysis were normal. The She was regularly followed by a pediatrician and a preauricular solitary mastocytoma was sensitive and pediatric dermatologist and had had normal develop- ‘‘annoying’’ to the patient. She was treated using ment. intralesional steroids several times and topical cortico- At the age of 10, more spots had slowly appeared on steroids as needed. Eventually, at age 19, she requested the neck, the V of the neck, the shoulders, and the back removal. Histopathology showed nodular infiltration of MC with prominent infiltrate of eosinophils extending throughout the thickness of the dermis and subcutaneous fibroadipose tissue (Figs 4 and 5). Histochemical stains for Giemsa, Leder, and Alcian blue confirmed MC (Fig. 6). At age 23, she was given acetaminophen with codeine and aspirin for neck and low back pain. This precipitated anaphylactic shock, requiring intubation and hospital- ization. Diagnosis of systemic mastocytosis was made based on results as follows: hemoglobin 8.1 g ⁄dL, white blood cell count 7,200 cell ⁄mL (neutrophils 86%, lym- phocytes 6.9%, monocytes 8.3%), platelet 267,000 ⁄mL, and a serum tryptase was >200 ng ⁄mL, and urine his- Figure 1. Preauricular mastocytoma: similar clinical picture tamine greater than two times normal limits. Bone to first presentation. Figure 2. Sister kicked her in this area, resulting in prompt Figure 3. Urticaria pigmentosa macules gradually increas- large bullae. ing in number over upper back. Note positive Darier’s sign. Chantorn and Shwayder: Death from Mast Cell Leukemia 607 Figure 6. Low-power view of preauricular biopsy Giemsa stain showing multiple mast cells. attacks per day consisting of tachycardia, flushing, mild shortness of breath, chest pressure, mild headache, and low back pain, lasting approximately 20 to 30 minutes Figure 4. Low-power view of preauricular area excision. Mast cell infiltrate throughout thickness of biopsy. each, and resolving without complications. She was admitted to the hospital for further examination and monitoring. Laboratory tests demonstrated hemoglobin of 13.3 g ⁄dL, white blood cell count 26,200 cell ⁄mL (neutrophils 58.5%, lymphocytes 9%, monocytes 2.5%, eosinophil 28.7%), absolute neutrophil count 15,327 cell ⁄mL, absolute eosinophil count 7,519 cell ⁄mL, and platelet count 122,000 ⁄mL. Repeat bone marrow aspi- rate smear showed that 79% of MC had atypical spindle- shaped morphology and confirmed the diagnosis of MC leukemia with rapid progression. Abdominal ultra- sonography revealed mild splenomegaly. Induction chemotherapy with cytarabine and ida- rubicin was started and induced some response. She subsequently underwent HLA identical sibling allo- genic peripheral blood stem cell transplantation, with fludarabine and busulfan as a conditioning regimen. Twelve days later, she started to engraft. Unfortu- Figure 5. High-power view of preauricular biopsy with dense nately, she continued to have episodes of histamine mast cell infiltrate. Note rare atypical multinucleated mast cells. release symptoms. Repeat bone marrow biopsy was done and demonstrated 70% of MC with sheets of atypical MC. Flow cytometric analysis revealed an marrow aspiration and biopsy showed that multiple atypical population of cells that expressed CD117, small aggregates of MC occupied 5% of the bone mar- CD25, CD58, CD63, and CD33, but were negative for row medullary space and stained strongly positive for CD2. Cytogenic studies were positive for a BCR-ADL tryptase.Rarespindle-shapedMCwerealsoseeninthis rearrangement. C-kit mutation analysis was not per- bone marrow study. Long bone survey was unremark- formed. These findings were consistent with persistent able. Computed tomography of the chest, abdomen, and MC leukemia. In addition, she had developed skin pelvis were normal except for an ectopic right pelvic rash, with a diagnosis of acute graft versus host disease, kidney. She was treated using systemic corticosteroids and was treated with high-dose systemic steroids and and H1 and H2 antihistamine. oral tacrolimus. During the 4 months after being diagnosed with sys- Her last admission was because of progressive temic mastocytosis, she had one or two mastocytosis and refractory edema. Upon hospitalization, she had 608 Pediatric Dermatology Vol. 29 No. 5 September ⁄ October 2012 developed fever with no evidence of any signs or symp- SM is characterized by multifocal infiltration of MC toms of infection. Cultures from blood and urine were in various organs, including bone marrow, gastrointes- examined and were negative. She received broad-spec- tinal tract, lymph nodes, liver, and spleen. The bone trum antibiotics, antiviral agents, and antifungal drugs, marrow is the most common documented site of MC but she continued to have fever and developed shock, accumulation outside of the skin (17). Mast cell leukemia requiring intubation and resuscitation, complicated by is a rare disorder, accounting for 1% of SM cases in one disseminated intravascular coagulopathy and metabolic review of 342 patients of SM from the Mayo Clinic (7). acidosis. She was unresponsive to treatment and died The clinical manifestation of SM results from 5 months after she was diagnosed with MC leukemia at MC-derived chemical mediators or infiltration of various the age of 23 years and 10 months. organs by neoplastic cells (4,18). Individuals with SM are Because of her death, we reviewed the earlier pathol- at certain risk of developing secondary hematologic ogy from her preauricular lesion. There were rare mul- malignancies, especially in myeloid leukemia (19). Indi- tinucleated MC within infiltrate (Fig. 5). Several of our viduals with MC leukemia usually have significant dermatopathologists and the National Institutes of organopathy but often present without cutaneous Health (NIH) reviewed this slide and thought that it was eruptions (9,18). consistent with cutaneous MC disease.
Recommended publications
  • Updates in Mastocytosis
    Updates in Mastocytosis Tryptase PD-L1 Tracy I. George, M.D. Professor of Pathology 1 Disclosure: Tracy George, M.D. Research Support / Grants None Stock/Equity (any amount) None Consulting Blueprint Medicines Novartis Employment ARUP Laboratories Speakers Bureau / Honoraria None Other None Outline • Classification • Advanced mastocytosis • A case report • Clinical trials • Other potential therapies Outline • Classification • Advanced mastocytosis • A case report • Clinical trials • Other potential therapies Mastocytosis symposium and consensus meeting on classification and diagnostic criteria for mastocytosis Boston, October 25-28, 2012 2008 WHO Classification Scheme for Myeloid Neoplasms Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Juvenile Myelomonocytic Leukemia Myelodysplastic Syndromes MDS/MPN, unclassifiable Chronic Myelogenous Leukemia MDS/MPN Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis Myeloproliferative Neoplasms Chronic Neutrophilic Leukemia Chronic Eosinophilic Leukemia, NOS Hypereosinophilic Syndrome Mast Cell Disease MPNs, unclassifiable Myeloid or lymphoid neoplasms Myeloid neoplasms associated with PDGFRA rearrangement associated with eosinophilia and Myeloid neoplasms associated with PDGFRB abnormalities of PDGFRA, rearrangement PDGFRB, or FGFR1 Myeloid neoplasms associated with FGFR1 rearrangement (EMS) 2017 WHO Classification Scheme for Myeloid Neoplasms Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia Atypical Chronic Myeloid Leukemia Juvenile Myelomonocytic
    [Show full text]
  • Late Effects Among Long-Term Survivors of Childhood Acute Leukemia in the Netherlands: a Dutch Childhood Leukemia Study Group Report
    0031-3998/95/3805-0802$03.00/0 PEDIATRIC RESEARCH Vol. 38, No.5, 1995 Copyright © 1995 International Pediatric Research Foundation, Inc. Printed in U.S.A. Late Effects among Long-Term Survivors of Childhood Acute Leukemia in The Netherlands: A Dutch Childhood Leukemia Study Group Report A. VAN DER DOES-VAN DEN BERG, G. A. M. DE VAAN, J. F. VAN WEERDEN, K. HAHLEN, M. VAN WEEL-SIPMAN, AND A. J. P. VEERMAN Dutch Childhood Leukemia Study Group,' The Hague, The Netherlands A.8STRAC ' Late events and side effects are reported in 392 children cured urogenital, or gastrointestinal tract diseases or an increased vul­ of leukemia. They originated from 1193 consecutively newly nerability of the musculoskeletal system was found. However, diagnosed children between 1972 and 1982, in first continuous prolonged follow-up is necessary to study the full-scale late complete remission for at least 6 y after diagnosis, and were effects of cytostatic treatment and radiotherapy administered treated according to Dutch Childhood Leukemia Study Group during childhood. (Pediatr Res 38: 802-807, 1995) protocols (70%) or institutional protocols (30%), all including cranial irradiation for CNS prophylaxis. Data on late events (relapses, death in complete remission, and second malignancies) Abbreviations were collected prospectively after treatment; late side effects ALL, acute lymphocytic leukemia were retrospectively collected by a questionnaire, completed by ANLL, acute nonlymphocytic leukemia the responsible pediatrician. The event-free survival of the 6-y CCR, continuous first complete remission survivors at 15 y after diagnosis was 92% (±2%). Eight late DCLSG, Dutch Childhood Leukemia Study Group relapses and nine second malignancies were diagnosed, two EFS, event free survival children died in first complete remission of late toxicity of HR, high risk treatment, and one child died in a car accident.
    [Show full text]
  • ICD-10-CM TABULAR LIST of DISEASES and INJURIES 2018 Addenda No Change Chapter 1 No Change Certain Infectious and Parasitic Diseases (A00-B99)
    ICD-10-CM TABULAR LIST of DISEASES and INJURIES 2018 Addenda No Change Chapter 1 No Change Certain infectious and parasitic diseases (A00-B99) No Change Intestinal infectious diseases (A00-A09) No Change A04 Other bacterial intestinal infections No Change A04.7 Enterocolitis due to Clostridium difficile Add A04.71 Enterocolitis due to Clostridium difficile, recurrent Add A04.72 Enterocolitis due to Clostridium difficile, not specified as recurrent No Change A05 Other bacterial foodborne intoxications, not elsewhere classified No Change Excludes1: Revise from Clostridium difficile foodborne intoxication and infection (A04.7) Revise to Clostridium difficile foodborne intoxication and infection (A04.7-) No Change Helminthiases (B65-B83) No Change B81 Other intestinal helminthiases, not elsewhere classified No Change Excludes1: Revise from angiostrongyliasis due to Parastrongylus cantonensis (B83.2) Revise to angiostrongyliasis due to: Add Angiostrongylus cantonensis (B83.2) Add Parastrongylus cantonensis (B83.2) No Change B81.3 Intestinal angiostrongyliasis Revise from Angiostrongyliasis due to Parastrongylus costaricensis Revise to Angiostrongyliasis due to: Add Angiostrongylus costaricensis Add Parastrongylus costaricensis No Change Chapter 2 No Change Neoplasms (C00-D49) No Change Malignant neoplasms of ill-defined, other secondary and unspecified sites (C76-C80) No Change C79 Secondary malignant neoplasm of other and unspecified sites Delete Excludes2: lymph node metastases (C77.0) No Change C79.1 Secondary malignant neoplasm of bladder
    [Show full text]
  • Hematopoietic and Lymphoid Neoplasm Coding Manual
    Hematopoietic and Lymphoid Neoplasm Coding Manual Effective with Cases Diagnosed 1/1/2010 and Forward Published August 2021 Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER Margaret (Peggy) Adamo, BS, AAS, RHIT, CTR, NCI SEER Lois Dickie, CTR, NCI SEER Serban Negoita, MD, PhD, CTR, NCI SEER Suggested citation: Ruhl J, Adamo M, Dickie L., Negoita, S. (August 2021). Hematopoietic and Lymphoid Neoplasm Coding Manual. National Cancer Institute, Bethesda, MD, 2021. Hematopoietic and Lymphoid Neoplasm Coding Manual 1 In Appreciation NCI SEER gratefully acknowledges the dedicated work of Drs, Charles Platz and Graca Dores since the inception of the Hematopoietic project. They continue to provide support. We deeply appreciate their willingness to serve as advisors for the rules within this manual. The quality of this Hematopoietic project is directly related to their commitment. NCI SEER would also like to acknowledge the following individuals who provided input on the manual and/or the database. Their contributions are greatly appreciated. • Carolyn Callaghan, CTR (SEER Seattle Registry) • Tiffany Janes, CTR (SEER Seattle Registry) We would also like to give a special thanks to the following individuals at Information Management Services, Inc. (IMS) who provide us with document support and web development. • Suzanne Adams, BS, CTR • Ginger Carter, BA • Sean Brennan, BS • Paul Stephenson, BS • Jacob Tomlinson, BS Hematopoietic and Lymphoid Neoplasm Coding Manual 2 Dedication The Hematopoietic and Lymphoid Neoplasm Coding Manual (Heme manual) and the companion Hematopoietic and Lymphoid Neoplasm Database (Heme DB) are dedicated to the hard-working cancer registrars across the world who meticulously identify, abstract, and code cancer data.
    [Show full text]
  • Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types Detection and Diagnosis
    cancer.org | 1.800.227.2345 Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that is not always the case. ● Can Acute Lymphocytic Leukemia (ALL) Be Found Early? ● Signs and Symptoms of Acute Lymphocytic Leukemia (ALL) ● Tests for Acute Lymphocytic Leukemia (ALL) Types of ALL Learn how ALL is classified and how this may affect your treatment options. ● Acute Lymphocytic Leukemia (ALL) Subtypes and Prognostic Factors Questions to Ask About ALL Here are some questions you can ask your cancer care team to help you better understand your ALL diagnosis and treatment options. ● Questions to Ask About Acute Lymphocytic Leukemia (ALL) 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Can Acute Lymphocytic Leukemia (ALL) Be Found Early? For many types of cancers, finding the cancer early makes it easier to treat. The American Cancer Society recommends screening tests for early detection of certain cancers1 in people without any symptoms. But at this time there are no special tests recommended to detect acute lymphocytic leukemia (ALL) early. The best way to find leukemia early is to report any possible signs or symptoms of leukemia (see Signs and symptoms of acute lymphoblastic leukemia) to the doctor right away. For people at increased risk of ALL Some people are known to have a higher risk of ALL (or other leukemias) because of a genetic disorder such as Down syndrome, or because they were previously treated with certain chemotherapy drugs or radiation.
    [Show full text]
  • Solitary Plasmacytoma: a Review of Diagnosis and Management
    Current Hematologic Malignancy Reports (2019) 14:63–69 https://doi.org/10.1007/s11899-019-00499-8 MULTIPLE MYELOMA (P KAPOOR, SECTION EDITOR) Solitary Plasmacytoma: a Review of Diagnosis and Management Andrew Pham1 & Anuj Mahindra1 Published online: 20 February 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Solitary plasmacytoma is a rare plasma cell dyscrasia, classified as solitary bone plasmacytoma or solitary extramedullary plasmacytoma. These entities are diagnosed by demonstrating infiltration of a monoclonal plasma cell population in a single bone lesion or presence of plasma cells involving a soft tissue mass, respectively. Both diseases represent a single localized process without significant plasma cell infiltration into the bone marrow or evidence of end organ damage. Clinically, it is important to classify plasmacytoma as having completely undetectable bone marrow involvement versus minimal marrow involvement. Here, we discuss the diagnosis, management, and prognosis of solitary plasmacytoma. Recent Findings There have been numerous therapeutic advances in the treatment of multiple myeloma over the last few years. While the treatment paradigm for solitary plasmacytoma has not changed significantly over the years, progress has been made with regard to diagnostic tools available that can risk stratify disease, offer prognostic value, and discern solitary plasmacytoma from quiescent or asymptomatic myeloma at the time of diagnosis. Summary Despite various studies investigating the use of systemic therapy or combined modality therapy for the treatment of plasmacytoma, radiation therapy remains the mainstay of therapy. Much of the recent advancement in the management of solitary plasmacytoma has been through the development of improved diagnostic techniques.
    [Show full text]
  • Compressive Myelopathy Caused by Isolated Epidural Myeloid Sarcoma with Systemic Mastocytosis
    Clinical Notes Compressive myelopathy caused by isolated epidural myeloid sarcoma with systemic mastocytosis. Rare presentation of a hematological malignancy Cyril J. Kurian, MBBS, Indira Madhavan, MBBS, MD, Prabhalakshmi K. Krishnankutty, MBBS, MD, Mekkattukunnel A. Andrews, MD, DM. eurological manifestations of acute leukemia are Ndue to direct involvement by meningeal infiltration and myeloid sarcoma; and indirect involvement by immunosuppression and treatment related side effects. It is rare for myeloid sarcoma to present without bone marrow involvement (isolated myeloid sarcoma or primary granulocytic sarcoma).1 It is even rarer for an isolated myeloid sarcoma to present in the epidural space. We evaluated a case of paraplegia admitted to our department. He had several atypical features that we would like to present in this report. A 39-year-old gentleman with a body weight of Figure 1 - Magnetic resonance imaging of thoracic spine T1W sagittal 58 kg presented with paresthesia and heaviness of view, arrow showing extradural mass at T6 level. both lower limbs of 4 days duration. He was found to have spastic paraplegia with bladder involvement and sensory level at T6. The clinical diagnosis of acute peripheral blood picture showed dimorphic anemia, transverse myelitis was made. Table 1 summarizes the occasional large cells with granular cytoplasm and nucleus with condensed chromatin, and no blast cells. laboratory investigations. The MRI study of the dorsal Ultrasound of the abdomen showed mild splenomegaly. spine (Figure 1) shows that a moderate sized enhancing Urine Bence Jones protein was absent. No M band was posterior epidural component was compressing the seen on serum protein electrophoresis. Bone marrow thecal sac and spinal cord.
    [Show full text]
  • Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distin
    Leukemia (2015) 29, 1115–1122 © 2015 Macmillan Publishers Limited All rights reserved 0887-6924/15 www.nature.com/leu ORIGINAL ARTICLE Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event M Jawhar1,8, J Schwaab1,8, S Schnittger2, K Sotlar3, H-P Horny3, G Metzgeroth1, N Müller1, S Schneider4, N Naumann1, C Walz3, T Haferlach2, P Valent5, W-K Hofmann1, NCP Cross6,7, A Fabarius1 and A Reiter1 To explore the molecular profile and its prognostic implication in systemic mastocytosis (SM), we analyzed the mutation status of granulocyte–macrophage colony-forming progenitor cells (CFU-GM) in patients with KIT D816V+ indolent SM (ISM, n = 4), smoldering SM (SSM, n = 2), aggressive SM (ASM, n = 1), SM with associated clonal hematologic non-mast cell lineage disorder (SM-AHNMD, n = 5) and ASM-AHNMD (n = 7). All patients with (A)SM-AHNMD (n = 12) carried 1–4 (median 3) additional mutations in 11 genes tested, most frequently TET2, SRSF2, ASXL1, CBL and EZH2. In multi-mutated (A)SM-AHNMD, KIT D816V+ single-cell-derived CFU-GM colonies were identified in 8/12 patients (median 60%, range 0–95). Additional mutations were identified in CFU-GM colonies in all patients, and logical hierarchy analysis indicated that mutations in TET2, SRSF2 and ASXL1 preceded KIT D816V. In ISM/SSM, no additional mutations were detected and CFU-GM colonies were exclusively KIT D816V−. These data indicate that (a) (A)SM-AHNMD is a multi-mutated neoplasm, (b) mutations in TET2, SRSF2 or ASXL1 precede KIT D816V in ASM-AHNMD, (c) KIT D816V is thus a phenotype modifier toward SM and (d) KIT D816V or other mutations are rare in CFU-GM colonies of ISM/SSM patients, which might explain at least in part their better prognosis.
    [Show full text]
  • Understanding Leukemia
    Understanding Leukemia Ray, CML survivor Revised 2012 Inside Front Cover A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to finding cures for blood cancer patients. Our research grants have funded many of today’s most promising advances; we are the leading source of free blood cancer information, education and support; and we advocate for blood cancer patients and their families, helping to ensure they have access to quality, affordable and coordinated care. Since 1954, we have been a driving force behind nearly every treatment breakthrough for blood cancer patients. We have invested more than $1 billion in research to advance therapies and save lives. Thanks to research and access to better treatments, survival rates for many blood cancer patients have doubled, tripled and even quadrupled. Yet we are far from done. Until there is a cure for cancer, we will continue to work hard—to fund new research, to create new patient programs and services, and to share information and resources about blood cancer. This booklet has information that can help you understand your finances, prepare questions, find answers and resources, and communicate better with members of your healthcare team. Our vision is that, one day, all people with blood cancers will either be cured or will be able to manage their disease so that they can experience a better quality of life. Today, we hope our expertise, knowledge and resources will make a difference in your journey. Louis J.
    [Show full text]
  • Acute Lymphoblastic Leukemia Following Hodgkin's Disease
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 10, No. 2 Copyright © 1980, Institute for Clinical Science, Inc. Acute Lymphoblastic Leukemia Following Hodgkin’s Disease ABDUS SALEEM, M.D.* and ROSALIE L. JOHNSTON, M.D. Departments of Pathology, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030 ABSTRACT Over 100 instances of acute leukemia have been reported in the course of Hodgkin’s disease. The type of leukemia almost always is nonlympho- blastic. Only five well documented cases of acute lymphoblastic leukemia (ALL) have been found by us in the world literature. One case who de­ veloped ALL six years after intensive radiotherapy for Hodgkin’s disease is herewith reported. The patient responded to treatment with Predisone, Vincristine and intrathecal methotrexate and maintained a complete remis­ sion on 6-mercaptopurine for nine months. When last seen, the bone marrow revealed a mild increase in blasts indicative of an early relapse. The incidence of second malignancy cervical area. He was treated initially with developing in the course of Hodgkin’s penicillin but had no significant im­ disease (HD) has been reported from 1.6 provement. An excisional node biopsy to 2.2 percent.1,13,14 Acute non-lympho- was performed and a diagnosis of blastic leukemias (ANLL) are among the Hodgkin’s disease, mixed cellularity, was commonest second tumors.2,14 There is made. The general architecture of the some controversy in the literature lymph node was partially effaced, though whether acute lymphoblastic leukemia several germinal centers were still pres­ (ALL) occurs in the course of Hodgkin’s ent.
    [Show full text]
  • Ibrutinib-Induced Lymphocytosis in Patients with Chronic Lymphocytic Leukemia: Correlative Analyses from a Phase II Study
    Leukemia (2014) 28, 2188–2196 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study SEM Herman1,5, CU Niemann1,5, M Farooqui1,5, J Jones1,2, RZ Mustafa1, A Lipsky1, N Saba1, S Martyr1, S Soto1, J Valdez1, JA Gyamfi1, I Maric3, KR Calvo3, LB Pedersen4, CH Geisler4, D Liu1, GE Marti1, G Aue1 and A Wiestner1 Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical results for patients with chronic lymphocytic leukemia (CLL). A treatment-induced rise in absolute lymphocyte count (ALC) has emerged as a class effect of kinase inhibitors in CLL and warrants further investigation. Here we report correlative studies in 64 patients with CLL treated with ibrutinib. We quantified tumor burden in blood, lymph nodes (LNs), spleen and bone marrow, assessed phenotypic changes of circulating cells and measured whole-blood viscosity. With just one dose of ibrutinib, the average increase in ALC was 66%, and in440% of patients the ALC peaked within 24 h of initiating treatment. Circulating CLL cells on day 2 showed increased Ki67 and CD38 expression, indicating an efflux of tumor cells from the tissue compartments into the blood. The kinetics and degree of the treatment-induced lymphocytosis was highly variable; interestingly, in patients with a high baseline ALC the relative increase was mild and resolution rapid. After two cycles of treatment the disease burden in the LN, bone marrow and spleen decreased irrespective of the relative change in ALC.
    [Show full text]
  • ©Ferrata Storti Foundation
    ORIGINAL ARTICLES Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT Karoline V. Gleixner, Matthias Mayerhofer, Karoline Sonneck, Alexander Gruze, Puchit Samorapoompichit, Christian Baumgartner, Francis Y. Lee, Karl J. Aichberger, Paul W. Manley, Doriano Fabbro, Winfried F. Pickl, Christian Sillaber, Peter Valent ABSTRACT From the Department of Internal Background and Objectives Medicine I, Division of Hematology & Hemostaseology (KVG, KS, CB, In a majority of all patients with systemic mastocytosis (SM) including those with KJA, CS, PV); Institute of Immunology mast cell leukemia (MCL), neoplastic mast cells (MC) display the D816V-mutated vari- (AG, WFP), Clinical Institute of ant of KIT. The respective oncoprotein, KIT D816V, exhibits constitutive tyrosine Medical and Chemical Laboratory kinase (TK) activity and has been implicated in malignant cell growth. Therefore, sev- Diagnostics (MM); Center of Anatomy eral attempts have been made to identify KIT D816V-targeting drugs. and Cell Biology, Medical University of Vienna, Austria (PS); Oncology Design and Methods Drug Discovery, Bristol-Myers Squibb, We examined the effects of the novel TK-inhibitor dasatinib alone and in combination Princeton, NJ, USA (FYL); Novartis Pharma AG, Basel, Switzerland with other targeted drugs on growth of neoplastic MC. (PWM, DF). Results Funding: this study was supported by Confirming previous studies, dasatinib was found to inhibit the TK activity of wild type the Fonds zur Förderung der (wt) KIT and KIT-D816V as well as growth and survival of neoplastic MC and of the Wissenschaftlichen Forschung in MCL cell line, HMC-1. The growth-inhibitory effects of dasatinib in HMC-1 cells were Österreich (FWF) grant #P-17205- found to be associated with a decrease in expression of CD2 and CD63.
    [Show full text]